Monday, June 30, 2025 6/30/2025

B7-H3-Targeted Contrast Agent for Ultrasonic Imaging of Breast Cancer

Award Number: R41CA213544
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/19/2016
PERIOD OF PERFORMANCE END DATE: 08/31/2018

Group Awards By:

View Award Description

B7-H3-Targeted Contrast Agent for Ultrasonic Imaging of Breast Cancer - ABSTRACT Breast cancer is the second leading cause of cancer-deaths in women in the United States and early detection can help improve survival. While mammography is the current first-line imaging technique for early breast cancer detection, its diagnostic accuracy is limited in women with dense breast tissue. Ultrasound is often performed as a second line test in women with dense breast tissue. However, due to its low specificity, it results in many false positive findings with unnecessary biopsies with increased associated health care costs. Dr. Willmann and his group at Stanford have recently identified and validated B7-H3 as a novel, highly specific neoangiogenesis marker in patients with breast cancer that allows differentiation of breast cancer from benign breast lesions with an AUC of up to 0.96. In a preliminary study, they tested an ultrasound contrast agent bearing antibodies to B7-H3 and showed in a transgenic mouse model that contrast-enhanced ultrasound could detect small foci of breast cancer. They have identified a peptide that binds to both murine and human B7-H3. Dr. Unger and his group at NuvOx Pharma developed the world’s #1 selling microbubble (MB) ultrasound contrast agent and have industry-leading expertise in targeting MB technologies. The overall goal of this grant proposal is to develop a novel clinical grade B7-H3-targeted ultrasound contrast agent that allows detection and characterization of breast cancer with both high sensitivity and specificity. In this collaborative effort we will create bioconjugates of the already identified peptide to B7-H3, incorporate them into newly designed clinical grade ultrasound contrast microbubbles (MB), confirm their binding to B7-H3 in vitro under flow shear stress conditions, and then confirm efficacy in a transgenic mouse model of breast cancer development. We will label the molecularly targeted MB with a fluorescent dye to allow in situ confirmation of in vivo B7-H3 target binding using microscopy. Successful completion of the Aims of this project may subsequently support formal development of B7-H3-targeted MB as a new drug candidate in Phase II.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2019 ( Subtotal = $0 )
2019	2016	NUVOX PHARMA, L.L.C.	1635 E. 18TH ST	TUCSON	AZ	85719	PIMA	USA	Cancer Control	001	1	4/11/2019	NEW	$79,528
2019	2016	NUVOX PHARMA, L.L.C.	1635 E. 18TH ST	TUCSON	AZ	85719	PIMA	USA	Cancer Control	000	1	1/22/2019	NEW	-$79,528
														Subtotal = $0

Issue Date FY: 2016 ( Subtotal = $298,820 )
2016	2016	NUVOX PHARMA LLC	1635 EAST 18TH STREET	TUCSON	AZ	85715	PIMA	USA	Cancer Control	000	1	9/19/2016	NEW	$298,820
														Subtotal = $298,820

Grand Total All Awards = $298,820

Top

All Categories

About

Search

Reports

Data Submission

Award Information

B7-H3-Targeted Contrast Agent for Ultrasonic Imaging of Breast Cancer

Award Number: R41CA213544

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/19/2016

PERIOD OF PERFORMANCE END DATE: 08/31/2018

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer